Online Learning Portal
Online Learning Portal
Hybrid Classes
We provide offline, online and recorded lectures in the same amount.
Personalised Mentoring
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant
Topicwise Mindmaps
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
Quality Content
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
DAILY NEWS ANALYSIS
PRINT
09 November, 2025
3 Min Read
A novel monoclonal antibody called MAM01, developed by US researchers, has shown promising results in providing strong protection against malaria in an early clinical trial.
Purpose:
MAM01 is specifically designed to prevent malaria infection by targeting a critical protein on the malaria parasite. The antibody targets the Plasmodium falciparum circumsporozoite protein (CSP), which is a key protein found on the surface of the malaria parasite’s sporozoite stage—the form that infects the human body.
Mechanism of Action:
The antibody works by blocking infection before the parasite can reach the bloodstream, preventing the parasite from infecting the liver and subsequently causing malaria.
Clinical Trial Results:
The early-stage clinical trial demonstrated that MAM01 provided dose-dependent full protection against malaria. Importantly, the antibody exhibited minimal side effects, suggesting that it could be a safe and effective alternative to current malaria prevention methods.
Administration:
MAM01 is administered via a single injection. This long-acting antibody offers immediate protection, with the potential to provide months-long protection against malaria after just one dose.
Target Population:
This treatment is especially beneficial for young children and pregnant women, two groups that are particularly vulnerable to malaria. The ability to provide prolonged protection with a single injection could dramatically reduce the burden of malaria in endemic regions.
Monoclonal antibodies (mAbs) are laboratory-made proteins designed to mimic the body's natural immune defenses. They are engineered to target specific molecules or cells related to diseases like cancer, infections, or autoimmune disorders.
The Term "Monoclonal":
The term "monoclonal" refers to the fact that these antibodies are clones of a single type of antibody, meaning they are all identical and recognize the same target molecule.
Production of Monoclonal Antibodies:
Monoclonal antibodies are produced by cloning a single B cell (a type of immune cell that produces antibodies) and allowing it to produce large quantities of the antibody. These antibodies are then purified and used for therapeutic purposes.
Specificity:
mAbs are highly specific, meaning they are designed to recognize and bind to only one target molecule with great precision. This high specificity helps minimize the risk of side effects compared to broader, less targeted treatments.
Applications:
Monoclonal antibodies have wide-ranging applications in medicine, including the treatment of:
Cancer (e.g., targeting tumor cells)
Autoimmune diseases (e.g., rheumatoid arthritis)
Infectious diseases (e.g., malaria, HIV)
The development of MAM01 could significantly change the way malaria is prevented, especially in endemic regions where access to vaccines and conventional treatments may be limited. A single dose providing long-lasting protection would not only reduce the risk of transmission but also offer an easier and more accessible way to protect vulnerable populations, such as pregnant women and children under five, who are at the highest risk of malaria-related deaths.
The development of MAM01 represents a promising advancement in malaria prevention. With its ability to provide long-term protection through a single injection, this monoclonal antibody could revolutionize malaria control, especially in vulnerable populations.
Source: THE HINDU
PRINT
08 November, 2025
4 Min Read
A novel monoclonal antibody called MAM01, developed by US researchers, has shown promising results in providing strong protection against malaria in an early clinical trial.
Purpose:
MAM01 is specifically designed to prevent malaria infection by targeting a critical protein on the malaria parasite. The antibody targets the Plasmodium falciparum circumsporozoite protein (CSP), which is a key protein found on the surface of the malaria parasite’s sporozoite stage—the form that infects the human body.
Mechanism of Action:
The antibody works by blocking infection before the parasite can reach the bloodstream, preventing the parasite from infecting the liver and subsequently causing malaria.
Clinical Trial Results:
The early-stage clinical trial demonstrated that MAM01 provided dose-dependent full protection against malaria. Importantly, the antibody exhibited minimal side effects, suggesting that it could be a safe and effective alternative to current malaria prevention methods.
Administration:
MAM01 is administered via a single injection. This long-acting antibody offers immediate protection, with the potential to provide months-long protection against malaria after just one dose.
Target Population:
This treatment is especially beneficial for young children and pregnant women, two groups that are particularly vulnerable to malaria. The ability to provide prolonged protection with a single injection could dramatically reduce the burden of malaria in endemic regions.
Monoclonal antibodies (mAbs) are laboratory-made proteins designed to mimic the body's natural immune defenses. They are engineered to target specific molecules or cells related to diseases like cancer, infections, or autoimmune disorders.
The Term "Monoclonal":
The term "monoclonal" refers to the fact that these antibodies are clones of a single type of antibody, meaning they are all identical and recognize the same target molecule.
Production of Monoclonal Antibodies:
Monoclonal antibodies are produced by cloning a single B cell (a type of immune cell that produces antibodies) and allowing it to produce large quantities of the antibody. These antibodies are then purified and used for therapeutic purposes.
Specificity:
mAbs are highly specific, meaning they are designed to recognize and bind to only one target molecule with great precision. This high specificity helps minimize the risk of side effects compared to broader, less targeted treatments.
Applications:
Monoclonal antibodies have wide-ranging applications in medicine, including the treatment of:
Cancer (e.g., targeting tumor cells)
Autoimmune diseases (e.g., rheumatoid arthritis)
Infectious diseases (e.g., malaria, HIV)
The development of MAM01 could significantly change the way malaria is prevented, especially in endemic regions where access to vaccines and conventional treatments may be limited. A single dose providing long-lasting protection would not only reduce the risk of transmission but also offer an easier and more accessible way to protect vulnerable populations, such as pregnant women and children under five, who are at the highest risk of malaria-related deaths.
The development of MAM01 represents a promising advancement in malaria prevention. With its ability to provide long-term protection through a single injection, this monoclonal antibody could revolutionize malaria control, especially in vulnerable populations.
Source: INDIAN EXPRESS
05 Apr, 26
A year after tensions arising from Operation Sindoor, India and Azerbaijan have taken steps to restore and normalise bilateral relations. The 6th round of Foreign Office Consultations, held in Baku, marked the first such engagement since 2022, signaling renewed diplomatic momentum. Recent Diplomatic Engagement During the consultations, bo
04 Apr, 26
The India–Australia Economic Cooperation and Trade Agreement has completed four years since its signing. Both countries now aim to build on this progress through strengthened collaboration and ambitious targets, including reaching AUD 100 billion in bilateral trade by 2030. What is the India–Australia Economic Cooperation and Tra
03 Apr, 26
A recent report by the Association for Democratic Reforms (ADR) analyses donations of ?20,000 or more declared to the Election Commission of India (ECI) by national political parties for FY 2024–25, highlighting transparency and accountability in political financing. Key Findings Massive Funding Surge Total donations to nationa
03 Apr, 26
Maritime chokepoints are narrow channels along global shipping routes where maritime traffic is concentrated. These points are geopolitically and economically critical, as they handle a large proportion of global trade, especially energy shipments. Current Relevance Over two-thirds of seaborne energy trade passes through a handful o
01 Apr, 26
Following the launch of Operation Epic Fury (U.S.) and Operation Roaring Lion (Israel), the geopolitical landscape has shifted fundamentally with the confirmed death of Iran’s Supreme Leader, Ayatollah Ali Khamenei.Iran retaliated through Operation True Promise 4, launching missile attacks against Israel and nearby Gulf states. The escala
05 Apr,2026
Our Popular Courses
Module wise Prelims Batches
Mains Batches
Test Series
24 × 7 Support :
8287714422
Whatsapp :
8010068998
Email Us: query@aspireias.com
My Notes
Geography And Environment
